POLE and carcinoma: Based on the Leiden classifier, we assessed the proportion of patients in whom POLE sequencing could be omitted without causing a risk-group shift; i.e., those with either clinicopathologic low-risk carcinoma and normal p53 staining (208/515), or stage III–IV carcinoma (103/515).